

Thailand Company Update

Siam Wellness Group

Bloomberg: SPA TB | Reuters: SPA.BK

Refer to important disclosures at the end of this report

Government Savings BankDBS Group

11 Mar 2021

BUY

Last Traded Price (10 Mar 2021): Bt9.05 (SET : 1,573.05)
Price Target 12-mth: Bt10.00 (10% upside) (Prev Bt8.60)


Analyst

Nantika WIANGPHOEM, CFA +66 28577836 nantikaw@th.dbs.com

What's New

- Recap of weak 2020 results due to the COVID-19 pandemic
- 1Q21 outlook remains soft due to new wave of COVID-19; q-o-q improvement expected from 2Q21 onwards
- Balance sheet remains healthy with potential new businesses
- Maintain BUY with higher DCF-based TP of Bt10

Price Relative



Forecasts and Valuation

| FY Dec (Btm) | 2019A | 2020A | 2021F | 2022F |
|----------------------------|-------|--------|--------|-------|
| Revenue | 1,384 | 427 | 778 | 1,196 |
| EBITDA | 418 | 16.7 | 125 | 410 |
| Pre-tax Profit | 291 | (217) | (108) | 172 |
| Net Profit | 245 | (202) | (86.7) | 138 |
| Net Pft (Pre Ex.) | 244 | (196) | (86.7) | 138 |
| Net Pft Gth (Pre-ex) (%) | 18.6 | nm | 55.8 | nm |
| EPS (Bt) | 0.43 | (0.4) | (0.1) | 0.16 |
| EPS Pre Ex. (Bt) | 0.43 | (0.3) | (0.1) | 0.16 |
| EPS Gth Pre Ex (%) | 19 | nm | 71 | nm |
| Diluted EPS (Bt) | 0.43 | (0.4) | (0.1) | 0.16 |
| Net DPS (Bt) | 0.16 | 0.0 | 0.0 | 0.06 |
| BV Per Share (Bt) | 1.99 | 1.59 | 0.89 | 0.99 |
| PE (X) | 21.0 | nm | nm | 56.1 |
| PE Pre Ex. (X) | 21.2 | nm | nm | 56.1 |
| P/Cash Flow (X) | 15.4 | 67.3 | 111.5 | 27.7 |
| EV/EBITDA (X) | 12.4 | 325.3 | 66.2 | 20.1 |
| Net Div Yield (%) | 1.7 | 0.0 | 0.0 | 0.7 |
| P/Book Value (X) | 4.6 | 5.7 | 10.2 | 9.1 |
| Net Debt/Equity (X) | 0.0 | 0.3 | 0.7 | 0.6 |
| ROAE (%) | 23.4 | (19.8) | (10.4) | 17.2 |
| Earnings Rev (%): | | 27 | 72 | 11 |
| Consensus EPS (Bt): | | (0.2) | (0.1) | 0.16 |
| Other Broker Recs: | | B: 5 | S: 3 | H: 0 |

Source of all data on this page: Company, DBSVTH, Bloomberg Finance L.P.

On the path to recovery

Investment Thesis:

Leader in spa industry. SPA is the largest spa & wellness service provider in Thailand by revenue. Its brands are well recognised among foreign and Thai customers, especially Let's Relax – the key brand that SPA is focusing on for its future expansion. It is also a prime beneficiary of Thailand's tourism activities accounting for c.70% of its revenue. Growth of international tourist arrivals expected over the long term bodes well for SPA's growth prospects. However, due to the global COVID-19 pandemic since late 1Q20, SPA's performance has been adversely affected. The company posted losses for the first time in 2020.

Losses to persist in FY21F; expected to turn profitable from FY22F onwards. Once fears of the pandemic diminish, we expect international tourist arrivals to rebound in late FY21F. Over the long term, we expect SPA's profits to be driven by; i) store expansion, both domestically and globally (via its asset-light model), ii) higher same-store sales growth (SSSG), iii) diversification by rolling out new service stores, and iv) improving margins.

Long-term benefits from mega trends. We believe its services, including spa and wellness, will be one of the future mega consumer trends with rapid growth potential. Alongside Thailand's growing tourism sector, SPA should also benefit given that the bulk of its revenue is from foreign tourists.

Valuation:

Our target price (TP) is based on discounted cash flow (DCF) (weighted average cost of capital (WACC) 8.3%, terminal growth 2.5%).

Where we differ:

We have a more conservative view on SPA's SSSG in FY22 and profit margins. As a result, our FY21F forecasts are lower than the street's.

Key Risks to Our View:

A sharp drop in international tourist arrivals, economic slowdown and more intense competition are some of the key risks.

At A Glance

| | |
|---------------------------|-------------|
| Issued Capital (m shrs) | 855 |
| Mkt. Cap (Btm/US\$m) | 7,738 / 252 |
| Major Shareholders (%) | |
| Jiravanstitt's Family | 17.3 |
| Wiboon Utsahajit | 11.1 |
| Pranee Suphawatanakiat | 9.3 |
| Free Float (%) | 55.8 |
| 3m Avg. Daily Val (US\$m) | 1.1 |

GIC Industry: Consumer Discretionary / Travel & Leisure



Live more, Bank less

WHAT'S NEW

Bottoming out in 1Q21

First losses since initial public offering (IPO): SPA posted a loss of Bt215m (vs net profit of Bt246m) in 2020 mainly due to the COVID-19 pandemic which led to a plunge in inbound tourists in 2020, from 39.8m in 2019 to 6.7m in 2020. Given that c.70% of SPA's revenue is from foreign tourists, its SSSG dropped 67% y-o-y. SPA has continued with measures to control costs including pay cuts and rental negotiations. However, this has not been sufficient to cover its revenue drop. The company's earnings were understated by Bt20m compared to pre-Thai Financial Reporting Standard 16 (TFRS 16). At end-2020, the company operated a total of 70 stores including five overseas stores (vs 63 stores at end-2019).

Expected to bottom out in 1Q21 before improving q-o-q from 2Q21 onwards: After the emergence of new COVID-19 clusters in Thailand in late December 2020, the Centre for COVID-19 Situation Administration (CCSA) announced several measures to contain the outbreak. In January 2021, SPA had to temporarily shut down some of its branches but reopened some stores in February 2021. Currently, c.70% of SPA's branches have reopened. The branches that remain closed are mostly located in tourist areas or in hotels that have not been reopened.

With the new pandemic wave, we expect SPA's performance to remain weak in 1Q21 before improving q-o-q in terms of revenue from 2Q21 onwards. This is due to the resumption of local activities and stronger recovery expected in 2H21 due to the gradual recovery of inbound tourism. The Thai government is now planning to reduce the quarantine period from 14 to 7 days for vaccinated and COVID-19-free foreign tourists from 1 April 2021. It may lift quarantine measures completely from 1 October 2021 if Thailand achieves its vaccination target by then. The relaxation of entry restrictions is pending approval by CCSA.

Balance sheet remains strong: At end 2020, SPA's net gearing was still at very low levels of 0.3x (excluding finance lease under TFRS16). The company had cash on hand of Bt115m along with credit facility and additional soft loan credit from the Government Savings Bank (GSB) totaling c. Bt100m, while its current cash burn rate per month is less than Bt10m. We believe that the company will not face any financial difficulties over the short to medium term. It does not have any plans to raise capital at the moment.

Potential upsides from hemp and new businesses:

According to its management, SPA is interested in hemp and cannabis related businesses. It has been preparing to launch spa treatments and products related to hemp and cannabis. Roll outs are now pending the government's green light. The company believes that these products will excite the market and draw new customers.

The company is also planning to launch new wellness businesses, mainly focusing on local guests in 2H21. SPA believes that its new business will receive the good feedback from customers due to the rising popularity of the wellness segment. This will help boost the company's revenue from 2H21 onwards. However, further details on this new business will only be disclosed to the public at a later date. Currently, we have not factored SPA's hemp and cannabis products as well as the new business, all of which could provide potential upside.

Fine-tune FY21/22F earnings forecast, based on impact of new pandemic wave.

We have reflected the softer-than-expected results in 2020 mainly on the higher-than-expected costs. In 2021, we assume a more conservative earnings before interest and taxes (EBIT) margin. We believe that the company's rental discount might drop from 2Q21 onwards after the COVID-19 pandemic eases. In 2021, we have assumed a more positive EBIT margin on better cost leverage as the company remains focused on cost controls. We are now pencilling in deeper negative SSSG numbers and EBIT margins (changes summarised in the table below) in our forecast models.

Key assumption revisions

| Growth | FY21F | | FY22F | |
|----------------|--------|---------|-------|-------|
| | Old | New | Old | New |
| SSSG – overall | 34% | 34% | 45% | 42% |
| EBIT margin | (8.1%) | (12.6%) | 13.7% | 14.8% |

Source: Company, DBS Vickers


Reiterate BUY call with higher TP of Bt10.0. After revising our earnings forecasts, our DCF-based TP inches up to Bt10.0. We believe that the market has priced in SPA's soft performance, as its share price is still a laggard compared to pre-COVID levels. In the long term, we believe the company should be able to resume its steady earnings growth alongside the expected recovery of tourism activities. Given the potential upside, we maintain our BUY call on SPA.

Siam Wellness Group

Company Background

SPA provides spa services to both local Thais and foreign customers under its brands "Rarinjinda Wellness Spa", "Let's Relax" and "Baan Suan Massage". In late 2018, the company added new services under the brands "Stretch Me by Let's Relax" (stretching services) and "Face Care by Let's Relax" (facial services).

Historical PE and PB bands



Source: Bloomberg Finance L.P., DBSVTH estimates

Quarterly / Interim Income Statement (Btm)

| FY Dec | 4Q2019 | 3Q2020 | 4Q2020 | % chg yoy | % chg qoq |
|-------------------------|-------------|---------------|---------------|----------------|----------------|
| Revenue | 338 | 76.2 | 81.4 | (75.9) | 6.7 |
| Cost of Goods Sold | (227) | (97.8) | (127) | (44.2) | 29.3 |
| Gross Profit | 111 | (21.6) | (45.1) | nm | (109.3) |
| Other Oper. (Exp)/Inc | (32.8) | (30.4) | (37.5) | 14.2 | 23.4 |
| Operating Profit | 78.2 | (51.9) | (82.6) | (205.7) | 59.1 |
| Other Non Opg (Exp)/Inc | 5.47 | 0.53 | 1.86 | (66.0) | 252.5 |
| Associates & JV Inc | 0.0 | 0.0 | 0.0 | nm | nm |
| Net Interest (Exp)/Inc | (2.2) | (2.7) | (4.6) | (105.6) | (68.3) |
| Exceptional Gain/(Loss) | 1.32 | 0.0 | 0.0 | nm | nm |
| Pre-tax Profit | 82.7 | (54.1) | (85.3) | nm | (57.6) |
| Tax | (13.7) | (0.8) | 14.4 | (205.3) | (1,870.7) |
| Minority Interest | 0.12 | 0.0 | 0.0 | (99.7) | nm |
| Net Profit | 69.2 | (55.0) | (71.0) | nm | 29.1 |
| Net Profit bef Except. | 67.8 | (55.0) | (71.0) | nm | 29.1 |
| EBITDA | 229 | 142 | 208 | (8.9) | 46.8 |
| Margins (%) | | | | | |
| Gross Margins | 32.9 | (28.3) | (55.5) | | |
| Opg Profit Margins | 23.1 | (68.1) | (101.5) | | |
| Net Profit Margins | 20.5 | (72.1) | (87.2) | | |

Source: Company, DBS Vickers

Siam Wellness Group

Key Assumptions

| FY Dec | 2018A | 2019A | 2020A | 2021F | 2022F |
|-----------------------|-------|-------|-------|-------|-------|
| Sales (Bt m) | 1,134 | 1,384 | 427 | 778 | 1,196 |
| Gross margin (%) | 33.9 | 31.9 | -18.7 | 4.4 | 25.6 |
| SGA/Sales (%) | 13.4 | 11.6 | 27.8 | 17.0 | 10.8 |
| Effective tax rate | 15% | 16% | 1% | 20% | 20% |
| Net profit margin (%) | 17.8 | 17.5 | -48.0 | -10.9 | 11.3 |

Segmental Breakdown

| FY Dec | 2018A | 2019A | 2020A | 2021F | 2022F |
|-----------------------|---------------|---------------|---------------|---------------|---------------|
| Revenues (Btm) | | | | | |
| Spa&wellness | 987 | 1,263 | 349 | 691 | 1,100 |
| Hotel&Food | 68 | 51 | 17 | 17 | 19 |
| Others | 70 | 70 | 61 | 70 | 77 |
| Total | 1,134 | 1,384 | 427 | 778 | 1,196 |
| (%) | | | | | |
| Spa&wellness | 87.0% | 91.3% | 81.7% | 88.8% | 92.0% |
| Hotel&Food | 6.0% | 3.7% | 4.0% | 2.2% | 1.6% |
| Others | 7.0% | 5.1% | 14.3% | 9.0% | 6.5% |
| Total | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

Income Statement (Btm)

| FY Dec | 2018A | 2019A | 2020A | 2021F | 2022F |
|-----------------------------|------------|------------|---------------|---------------|------------|
| Revenue | 1,134 | 1,384 | 427 | 778 | 1,196 |
| Cost of Goods Sold | (750) | (943) | (507) | (744) | (890) |
| Gross Profit | 384 | 441 | (79.7) | 34.6 | 306 |
| Other Opng (Exp)/Inc | (152) | (161) | (119) | (132) | (129) |
| Operating Profit | 232 | 281 | (198) | (97.7) | 177 |
| Other Non Opg (Exp)/Inc | 18.2 | 19.5 | 8.71 | 15.9 | 24.4 |
| Associates & JV Inc | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest (Exp)/Inc | (8.8) | (10.5) | (21.5) | (26.6) | (29.0) |
| Exceptional Gain/(Loss) | 0.0 | 1.64 | (6.0) | 0.0 | 0.0 |
| Pre-tax Profit | 241 | 291 | (217) | (108) | 172 |
| Tax | (35.4) | (45.2) | 15.0 | 21.7 | (34.5) |
| Minority Interest | 0.0 | (0.5) | 0.0 | 0.0 | 0.0 |
| Preference Dividend | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 206 | 245 | (202) | (86.7) | 138 |
| Net Profit before Except. | 206 | 244 | (196) | (86.7) | 138 |
| EBITDA | 346 | 418 | 16.7 | 125 | 410 |
| Growth | | | | | |
| Revenue Gth (%) | 19.7 | 22.0 | (69.1) | 82.3 | 53.7 |
| EBITDA Gth (%) | 19.3 | 20.8 | (96.0) | 647.3 | 228.1 |
| Opg Profit Gth (%) | 17.1 | 21.1 | (170.7) | (50.8) | (281.1) |
| Net Profit Gth (Pre-ex) (%) | 17.4 | 18.6 | nm | 55.8 | nm |
| Margins & Ratio | | | | | |
| Gross Margins (%) | 33.9 | 31.9 | (18.7) | 4.4 | 25.6 |
| Opg Profit Margin (%) | 20.4 | 20.3 | (46.5) | (12.6) | 14.8 |
| Net Profit Margin (%) | 18.1 | 17.7 | (47.4) | (11.1) | 11.5 |
| ROAE (%) | 23.8 | 23.4 | (19.8) | (10.4) | 17.2 |
| ROA (%) | 16.2 | 17.0 | (9.7) | (3.3) | 5.0 |
| ROCE (%) | 17.3 | 18.3 | (10.6) | (4.1) | 5.9 |
| Div Payout Ratio (%) | 41.6 | 36.0 | N/A | N/A | 40.0 |
| Net Interest Cover (x) | 26.2 | 26.8 | (9.2) | (3.7) | 6.1 |

Source: Company, DBSVTH

Siam Wellness Group

Quarterly Income Statement (Btm)

| FY Dec | 4Q2019 | 1Q2020 | 2Q2020 | 3Q2020 | 4Q2020 |
|-------------------------|-------------|-------------|---------------|---------------|---------------|
| Revenue | 338 | 238 | 31.5 | 76.2 | 81.4 |
| Cost of Goods Sold | (227) | (201) | (81.6) | (97.8) | (127) |
| Gross Profit | 111 | 37.1 | (50.1) | (21.6) | (45.1) |
| Other Oper. (Exp)/Inc | (32.8) | (30.3) | (20.5) | (30.4) | (37.5) |
| Operating Profit | 78.2 | 6.83 | (70.7) | (51.9) | (82.6) |
| Other Non Opg (Exp)/Inc | 5.47 | 5.74 | 0.59 | 0.53 | 1.86 |
| Associates & JV Inc | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest (Exp)/Inc | (2.2) | (8.6) | (5.6) | (2.7) | (4.6) |
| Exceptional Gain/(Loss) | 1.32 | 0.0 | (6.0) | 0.0 | 0.0 |
| Pre-tax Profit | 82.7 | 3.99 | (81.7) | (54.1) | (85.3) |
| Tax | (13.7) | 0.36 | 1.06 | (0.8) | 14.4 |
| Minority Interest | 0.12 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 69.2 | 4.35 | (80.6) | (55.0) | (71.0) |
| Net Profit bef Except. | 67.8 | 4.35 | (74.6) | (55.0) | (71.0) |
| EBITDA | 229 | 152 | 106 | 142 | 208 |

Growth

| | | | | | |
|-----------------------------|-------|--------|-----------|--------|------|
| Revenue Gth (%) | (8.2) | (29.6) | (86.8) | 142.1 | 6.7 |
| EBITDA Gth (%) | 11.1 | (33.4) | (30.5) | 34.2 | 46.8 |
| Opg Profit Gth (%) | (2.4) | (91.3) | (1,134.7) | (26.5) | 59.1 |
| Net Profit Gth (Pre-ex) (%) | 0.2 | (93.6) | (1,815.4) | (26.4) | 29.1 |

Margins

| | | | | | |
|------------------------|------|------|---------|--------|---------|
| Gross Margins (%) | 32.9 | 15.6 | (159.3) | (28.3) | (55.5) |
| Opg Profit Margins (%) | 23.1 | 2.9 | (224.5) | (68.1) | (101.5) |
| Net Profit Margins (%) | 20.5 | 1.8 | (256.1) | (72.1) | (87.2) |

Balance Sheet (Btm)

| FY Dec | 2018A | 2019A | 2020A | 2021F | 2022F |
|-------------------------------|--------------|--------------|--------------|--------------|--------------|
| Net Fixed Assets | 1,067 | 1,083 | 1,075 | 1,088 | 1,014 |
| Invts in Associates & JVs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other LT Assets | 126 | 144 | 1,326 | 1,337 | 1,364 |
| Cash & ST Invts | 111 | 126 | 115 | 26.7 | 126 |
| Inventory | 31.0 | 39.9 | 40.3 | 58.9 | 70.5 |
| Debtors | 23.5 | 37.2 | 21.8 | 53.8 | 82.7 |
| Other Current Assets | 9.65 | 86.3 | 54.8 | 99.9 | 154 |
| Total Assets | 1,369 | 1,516 | 2,632 | 2,664 | 2,811 |
| ST Debt | 90.0 | 84.9 | 103 | 103 | 103 |
| Creditor | 83.4 | 96.7 | 44.7 | 106 | 126 |
| Other Current Liab | 50.7 | 63.5 | 213 | 218 | 223 |
| LT Debt | 126 | 80.2 | 288 | 448 | 528 |
| Other LT Liabilities | 48.8 | 59.0 | 1,078 | 1,030 | 983 |
| Shareholder's Equity | 970 | 1,132 | 905 | 759 | 847 |
| Minority Interests | 0.0 | 0.01 | 0.0 | 0.0 | 0.0 |
| Total Cap. & Liab. | 1,369 | 1,516 | 2,632 | 2,664 | 2,811 |
| Non-Cash Wkg. Capital | (69.9) | 3.21 | (141) | (112) | (42.2) |
| Net Cash/(Debt) | (105) | (39.4) | (277) | (525) | (506) |
| Debtors Turn (avg days) | 5.8 | 8.0 | 25.2 | 17.7 | 20.8 |
| Creditors Turn (avg days) | 47.2 | 39.8 | 85.9 | 51.3 | 62.1 |
| Inventory Turn (avg days) | 16.4 | 15.7 | 48.7 | 33.7 | 34.6 |
| Asset Turnover (x) | 0.9 | 1.0 | 0.2 | 0.3 | 0.4 |
| Current Ratio (x) | 0.8 | 1.2 | 0.6 | 0.6 | 1.0 |
| Quick Ratio (x) | 0.6 | 0.7 | 0.4 | 0.2 | 0.5 |
| Net Debt/Equity (X) | 0.1 | 0.0 | 0.3 | 0.7 | 0.6 |
| Net Debt/Equity ex MI (X) | 0.1 | 0.0 | 0.3 | 0.7 | 0.6 |
| Capex to Debt (%) | 101.9 | 95.7 | 36.1 | 40.6 | 21.9 |
| Z-Score (X) | NA | NA | NA | NA | NA |

Source: Company, DBSVTH

Siam Wellness Group

Cash Flow Statement (Btm)

| FY Dec | 2018A | 2019A | 2020A | 2021F | 2022F |
|-------------------------|---------------|--------------|--------------|--------------|--------------|
| Pre-Tax Profit | 241 | 291 | (217) | (108) | 172 |
| Dep. & Amort. | 96.0 | 118 | 206 | 207 | 208 |
| Tax Paid | (35.4) | (45.2) | 15.0 | 21.7 | (34.5) |
| Assoc. & JV Inc/(loss) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Chg in Wkg.Cap. | 33.6 | (29.6) | 72.5 | (50.5) | (66.5) |
| Other Operating CF | (16.8) | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Operating CF | 318 | 334 | 76.7 | 69.4 | 280 |
| Capital Exp.(net) | (220) | (158) | (141) | (224) | (138) |
| Other Invs.(net) | 43.9 | (41.1) | 73.1 | 0.0 | 0.0 |
| Invs in Assoc. & JV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Div from Assoc & JV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Investing CF | (43.2) | (16.1) | (63.5) | (93.3) | (67.7) |
| Net Investing CF | (219) | (215) | (132) | (317) | (206) |
| Div Paid | (39.9) | (85.5) | (17.1) | 0.0 | (55.2) |
| Chg in Gross Debt | (61.5) | (46.9) | 372 | 160 | 80.0 |
| Capital Issues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Financing CF | 15.1 | (4.0) | 23.2 | 0.0 | 0.0 |
| Net Financing CF | (86.3) | (136) | 378 | 160 | 24.9 |
| Currency Adjustments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Chg in Cash | 12.7 | (17.5) | 323 | (87.9) | 98.9 |
| Opg CFPS (Bt) | 0.50 | 0.64 | 0.01 | 0.14 | 0.40 |
| Free CFPS (Bt) | 0.17 | 0.31 | (0.1) | (0.2) | 0.17 |

Source: Company, DBSVTH

Target Price & Ratings History



Note : Share price and target price are adjusted for corporate actions.

| S.No. | Date of Report | Closing Price | 12-mth Target Price | Rating |
|-------|----------------|---------------|---------------------|--------|
| 1: | 28 May 20 | 7.45 | 8.80 | BUY |
| 2: | 27 Aug 20 | 6.70 | 8.80 | BUY |
| 3: | 14 Dec 20 | 7.55 | 8.80 | BUY |
| 4: | 07 Jan 21 | 6.70 | 8.60 | BUY |

Source: DBSVTH

Analyst: Nantika WIANGPHOEM, CFA

THAI-CAC (as of Jun 2019)






Corporate Governance CG Rating (as of Oct 2019)

THAI-CAC is Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of May 2018) are categorised into:

Corporate Governance CG Rating is based on Thai Institute of Directors (IOD)'s annual assessment of corporate governance practices of listed companies. The assessment covers 235 criteria in five categories including board responsibilities (35% weighting), disclosure and transparency (20%), role of stakeholders (20%), equitable treatment of shareholders (10%) and rights of shareholders (15%). The IOD then assigns numbers of logos to each company based on their scoring as follows:

n/a



| Score | Description | |
|-----------|---|--------------|
| Declared | Companies that have declared their intention to join CAC | |
| Certified | Companies certified by CAC. | |
| Score | Range Number of Logo | Description |
| 90-100 |  | Excellent |
| 80-89 |  | Very Good |
| 70-79 |  | Good |
| 60-69 |  | Satisfactory |
| 50-59 |  | Pass |
| <50 | No logo given | N/A |

DBSVTH recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 11 Mar 2021 07:02:28 (THA)

Dissemination Date: 11 Mar 2021 07:07:52 (THA)

Sources for all charts and tables are DBSVTH unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Vickers Securities (Thailand) Co Ltd ("DBSVTH"). This report is solely intended for the clients of DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Vickers Securities (Thailand) Co Ltd ("DBSVTH").

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 28 Feb 2021.
2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.


Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

| | |
|------------------|---|
| General | This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. |
| Australia | <p>This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.</p> <p>DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.</p> <p>Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.</p> |
| Hong Kong | <p>This report has been prepared by an entity(ies) which is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited, a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.</p> <p>For any query regarding the materials herein, please contact Carol Wu (Reg No. AH8283) at dbsvhk@dbs.com</p> |
| Indonesia | This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia. |
| Malaysia | <p>This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBRS"). Recipients of this report, received from ADBRS are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBRS (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.</p> <p style="text-align: right;">  Wong Ming Tek, Executive Director, ADBRS </p> |
| Singapore | This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report. |

| | |
|---|---|
| Thailand | This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd. |
| United Kingdom | <p>This report is produced by DBS Vickers Securities (Thailand) Co Ltd which is regulated by the Securities and Exchange Commission, Thailand.</p> <p>This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.</p> <p>In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.</p> |
| Dubai International Financial Centre | This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608 - 610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it. |
| United Arab Emirates | This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent. |
| United States | This report was prepared by DBS Vickers Securities (Thailand) Co Ltd ("DBSVTH"). DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate. |
| Other jurisdictions | In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. |

DBS Regional Research Offices

HONG KONG

DBS (Hong Kong) Ltd

Contact: Carol Wu
13th Floor One Island East,
18 Westlands Road,
Quarry Bay, Hong Kong
Tel: 852 3668 4181
Fax: 852 2521 1812
e-mail: dbsvhk@dbs.com

MALAYSIA

AllianceDBS Research Sdn Bhd

Contact: Wong Ming Tek
19th Floor, Menara Multi-Purpose,
Capital Square,
8 Jalan Munshi Abdullah 50100
Kuala Lumpur, Malaysia.
Tel.: 603 2604 3333
Fax: 603 2604 3921
e-mail: general@alliancedbs.com
Co. Regn No. 198401015984 (128540-U)

SINGAPORE

DBS Bank Ltd

Contact: Janice Chua
12 Marina Boulevard,
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: 65 6878 8888
e-mail: groupresearch@dbs.com
Company Regn. No. 196800306E

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul
989 Siam Piwat Tower Building,
9th, 14th-15th Floor
Rama 1 Road, Pathumwan,
Bangkok Thailand 10330
Tel. 66 2 857 7831
Fax: 66 2 658 1269
e-mail: research@th.dbs.com
Company Regn. No 0105539127012
Securities and Exchange Commission, Thailand

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif
DBS Bank Tower
Ciputra World 1, 32/F
Jl. Prof. Dr. Satrio Kav. 3-5
Jakarta 12940, Indonesia
Tel: 62 21 3003 4900
Fax: 6221 3003 4943
e-mail: indonesiaresearch@dbs.com